A case of a mixed overdose involving kratom (Mitragyna speciosa) leading to serotonin syndrome

Main Article Content

H. Reid Zweifel
Jonathan Browne
Jeffrey M Levine

Abstract

Objective: Drug overdose deaths have risen precipitously over the past two years in the United States. Polysubstance overdose with opiates and amphetamines have been of particular concern. Kratom (Mitragyna speciosa) is an unregulated widely available herb with both stimulant and opiate μ-receptor activity. Studies suggest that its use is quickly increasing.


Case: We describe a patient who presented to a psychiatric hospital with a mixed toxic syndrome due to chronic kratom and prescribed SSRI use compounded by acute intake of methamphetamine. The patient displayed psychosis, tremulousness, myoclonus, and extreme anxiety. Her clinical picture was consistent with both serotonin syndrome and opiate withdrawal.


Conclusion: We call attention to this case because polysubstance overdoses are common, and kratom is widely available. Complex toxic presentations that involve kratom are likely to be increasingly encountered.

Downloads

Download data is not yet available.

Article Details

How to Cite
Zweifel, H. R., Browne, J., & Levine, J. M. (2021). A case of a mixed overdose involving kratom (Mitragyna speciosa) leading to serotonin syndrome. Medical Science and Discovery, 8(12), 735–737. https://doi.org/10.36472/msd.v8i12.626
Section
Case Reports

References

Ahmad FB, Rosson LM, Sutton P. Provisional drug overdose death counts. National Center for Health Statistics. 2021.

O’Donnell J, Gladden RM, Mattson CL, Hunter CT, Davis NL. Vital signs: Characteristics of drug overdose deaths involving opioids and stimulants—24 states and the District of Columbia, January–June 2019. Morbidity and Mortality Weekly Report. 2020 Sep 4;69(35):1189.

Veltri C, Grundmann O. Current perspectives on the impact of Kratom use. Substance abuse and rehabilitation. 2019;10:23.

Sanderson M, Rowe A. Kratom. CMAJ. 2019 Oct 7;191(40):E1105-.

Ellis CR, Racz R, Kruhlak NL, Kim MT, Zakharov AV, Southall N, Hawkins EG, Burkhart K, Strauss DG, Stavitskaya L. Evaluating kratom alkaloids using PHASE. PloS one. 2020 Mar 3;15(3):e0229646.

Grundmann O. Patterns of kratom use and health impact in the US—results from an online survey. Drug and alcohol dependence. 2017 Jul 1;176:63-70.

Fluyau D, Revadigar N. Biochemical benefits, diagnosis, and clinical risks evaluation of kratom. Frontiers in psychiatry. 2017 Apr 24;8:62.

Sharma A, Kamble SH, León F, Chear NJ, King TI, Berthold EC, Ramanathan S, McCurdy CR, Avery BA. Simultaneous quantification of ten key Kratom alkaloids in Mitragyna speciosa leaf extracts and commercial products by ultra‐performance liquid chromatography− tandem mass spectrometry. Drug testing and analysis. 2019 Aug;11(8):1162-71.

Lydecker AG, Sharma A, McCurdy CR, Avery BA, Babu KM, Boyer EW. Suspected adulteration of commercial kratom products with 7-hydroxymitragynine. Journal of Medical Toxicology. 2016 Dec;12(4):341-9.

Matsumoto K, Horie S, Ishikawa H, Takayama H, Aimi N, Ponglux D, Watanabe K. (2004). Antinociceptive effect of 7-hydroxymitragynine in mice: Discovery of an orally active opioid analgesic from the Thai medicinal herb Mitragyna speciosa. Life Sciences 2004; 74:2143-2155.

Raehal KM, Walker JK, Bohn LM. Morphine side effects in β-arrestin 2 knockout mice. Journal of Pharmacology and Experimental Therapeutics. 2005 Sep 1;314(3):1195-201.

Kruegel AC, Grundmann O. The medicinal chemistry and neuropharmacology of kratom: a preliminary discussion of a promising medicinal plant and analysis of its potential for abuse. Neuropharmacology. 2018 May 15;134:108-20.

Suhaimi FW, Yusoff NH, Hassan R, Mansor SM, Navaratnam V, Müller CP, Hassan Z. Neurobiology of Kratom and its main alkaloid mitragynine. Brain research bulletin. 2016 Sep 1;126:29-40.

Kumarnsit E, Vongvatcharanon U, Keawpradub N, Intasaro P. Fos-like immunoreactivity in rat dorsal raphe nuclei induced by alkaloid extract of Mitragyna speciosa. Neuroscience letters. 2007 Apr 12;416(2):128-32.

Swogger MT, Hart E, Erowid F, Erowid E, Trabold N, Yee K, Parkhurst KA, Priddy BM, Walsh Z. Experiences of kratom users: a qualitative analysis. Journal of psychoactive Drugs. 2015 Oct 20;47(5):360-7.

Olsen EO, O’Donnell J, Mattson CL, Schier JG, Wilson N. Notes from the field: unintentional drug overdose deaths with kratom detected—27 states, July 2016–December 2017. Morbidity and Mortality Weekly Report. 2019 Apr 12;68(14):326.

Hassan Z, Muzaimi M, Navaratnam V, Yusoff NH, Suhaimi FW, Vadivelu R, Vicknasingam BK, Amato D, von Hörsten S, Ismail NI, Jayabalan N. From Kratom to mitragynine and its derivatives: physiological and behavioural effects related to use, abuse, and addiction. Neuroscience & Biobehavioral Reviews. 2013 Feb 1;37(2):138-51.

Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. Qjm. 2003 Sep 1;96(9):635-42.

Madden JT, Reyna NC, Pentkowski NS. Antagonizing serotonin 2A (5-HT2A) receptors attenuates methamphetamine-induced reward and blocks methamphetamine-induced anxiety-like behaviors in adult male rats. Drug and Alcohol Dependence. 2020 Oct 1;215:108178.

Singh D, Müller CP, Murugaiyah V, Hamid SB, Vicknasingam BK, Avery B, Chear NJ, Mansor SM. Evaluating the hematological and clinical-chemistry parameters of kratom (Mitragyna speciosa) users in Malaysia. Journal of ethnopharmacology. 2018 Mar 25;214:197-206.

Sheleg SV, Collins GB. A coincidence of addiction to “Kratom” and severe primary hypothyroidism. Journal of addiction medicine. 2011 Dec 1;5(4):300-1.

Philipp AA, Meyer MR, Wissenbach DK, Weber AA, Zoerntlein SW, Zweipfenning PG, Maurer HH. Monitoring of kratom or Krypton intake in urine using GC-MS in clinical and forensic toxicology. Analytical and bioanalytical chemistry. 2011 Apr;400(1):127-35.

Stanciu CN, Gnanasegaram SA, Ahmed S, Penders T. Kratom withdrawal: a systematic review with case series. Journal of psychoactive drugs. 2019 Jan 1;51(1):12-8.